A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Group, 20-week Safety, Tolerability, And Efficacy Study Of Pd 0360324 In Adult Subjects With Chronic Pulmonary Sarcoidosis
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2014
Price : $35 *
At a glance
- Drugs PD 360324 (Primary)
- Indications Pulmonary sarcoidosis
- Focus Therapeutic Use
- Sponsors Pfizer
- 12 Aug 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 13 Jan 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
- 16 Dec 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.